Biomea Fusion, Inc. $BMEA

By Microcap Ledger desk · CIK 0001840439

Facts as of Oct 11, 2026, 08:10 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange: Nasdaq Global Select Market
Sector: Pharmaceutical Preparations
Headquarters: San Carlos, CA
Fiscal year end: December 31
Shares outstanding: 72,483,852 [10-Q 2026-08-05]
as of 2026-07-31

Sources: [10-K 2026-03-24]

What the company doesAI summary of filing

Biomea Fusion is a clinical-stage company developing oral, small molecule drugs to treat diabetes, obesity, and other metabolic diseases. The company has two main product candidates: icovamenib, a menin inhibitor in Phase II development for type 1 and type 2 diabetes, and BMF-650, a GLP-1 receptor agonist in Phase I development for obesity. Biomea Fusion is pre-revenue and has not generated any commercial sales, relying on capital raises to fund its research and development operations. [10-K 2026-03-24]

Segments: Icovamenib (menin inhibitor for diabetes), BMF-650 (GLP-1 receptor agonist for obesity)

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
6 months to Jun 2026	—	−$20.74M	−$21.70M	$34.82M	[10-Q 2026-08-05]
FY ended Dec 2025	—	−$61.80M	−$70.37M	$55.81M	[10-K 2026-03-24]
FY ended Dec 2024	—	−$138.43M	−$119.89M	$58.28M	[10-K 2026-03-24]

Quarterly cash burn: −$10.85M
Cash runway Estimate: ~9.6 months

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2024-10-23	36,238,687	[10-Q 2024-10-29]
2025-03-24	37,572,250	[10-K 2025-03-31]
2025-04-29	37,572,250	[10-Q 2025-05-05]
2025-08-01	59,508,518	[10-Q 2025-08-05]
2025-10-31	70,703,639	[10-Q 2025-11-04]
2026-03-20	72,299,440	[10-K 2026-03-24]
2026-05-02	72,299,440	[10-Q 2026-05-11]
2026-07-31	72,483,852	[10-Q 2026-08-05]

Shelf registration: S-3 filed 2025-08-05; declared effective 2025-08-15 [S-3 2025-08-05]

Listing status

Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-03-27. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

Date	Event	Details	Deadline	Filing
2025-03-27	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2025-03-27]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
Date	Insider	Type	Shares	Price	Filing
2025-12-11	Erdtmann Rainer M	buy	30,000	$1.43	[4 2025-12-15]
2025-12-02	Hitchcock Michael J.M.	buy	100,000	$0.99	[4 2025-12-04]

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-09-22	424B5	Prospectus or prospectus supplement
2026-09-22	8-K	Other events
2026-08-05	10-Q	Quarterly report
2026-06-11	8-K	Shareholder vote results
2026-05-11	10-Q	Quarterly report
2026-05-11	8-K	Results of operations
2026-04-28	8-K	Regulation FD disclosure; Other events
2026-04-27	DEF 14A	Proxy statement
2026-03-24	10-K	Annual report
2026-03-24	8-K	Results of operations
2026-02-25	8-K	Regulation FD disclosure
2026-02-17	13G/A	Beneficial ownership report (5%+ holder)

Facts as of Oct 11, 2026, 08:10 AM UTC. Small caps move fast; check the latest filings.